Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;24(1):321-329.
doi: 10.31557/APJCP.2023.24.1.321.

Profiling the Expression and Prognostic Values of FYN, A Non-Receptor Tyrosine Kinase, in Different Histological Types of Epithelial Ovarian Cancer

Wiyada Dankai  1 , Surapan Khunamornpong  1 , Prapaporn Suprasert  2 , Suree Lekawanvijit  1
Affiliations

Profiling the Expression and Prognostic Values of FYN, A Non-Receptor Tyrosine Kinase, in Different Histological Types of Epithelial Ovarian Cancer

Wiyada Dankai et al. Asian Pac J Cancer Prev. .

Abstract

Objective: This study was aimed at evaluating FYN expression among different histologic types of epithelial ovarian cancer (EOC) and its associated prognostics.

Methods: The FYN expression levels using quantitative real-time PCR method were evaluated in 98 primary EOC. Receiver operating characteristic curve were used to select an optimal cut-off value for determining the presence or absence of a disease progression.

Result: The median level of FYN expression varied among different EOC types, being the highest in high-grade serous carcinomas and the lowest in clear cell carcinomas (CCC). Using the cutoff FYN value to predict disease progression, the FYN-positive group had a poorer progression-free survival (PFS) compared to the FYN-negative group (p = 0.001). In multivariate Cox regression analysis, FYN expression was an independent predictor for disease progression (Hazard ratio = 2.30; 95% CI: 1.21- 4.38; p = 0.011). In subgroup analysis, FYN expression was significantly associated with lower PFS in early stage CCC patients (p = 0.009).

Conclusion: FYN expression is variable among different types of EOC while impacting on the prognostic values in patients with early stage CCC.

Keywords: Fyn; Ovarian Cancer; clear cell carcinomas; disease progression; non-receptor tyrosine kinase protein.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
The Expression Levels of FYN mRNA in Differentiating Histological Subtypes of Ovarian Cancer (Kruskal-Wallis equality-of-populations rank test, p= 0.0006)
Figure 2
Figure 2
The Relative Expression Levels of FYN mRNA between the EOC Patient Groups with and without Disease Progression (Mann-Whitney U test, p = 0.0005)
Figure 3
Figure 3
The ROC Curve Analysis of FYN Expression for Prediction of Disease Progression in EOC Patients
Figure 4
Figure 4
Kaplan-Meier Progression-Free Survival Plot of EOC Patients Stratified by FYN Expression Status (log-rank test; p = 0.0012)
Figure 5
Figure 5
Kaplan-Meier Progression-Free Survival Plots of Patients with Different Types of EOC stratified by FYN expression status. A, clear cell carcinomas (CCC); B, high-grade serous carcinomas (HGSC); C, other high-grade carcinomas; D, low-grade carcinomas
Figure 6
Figure 6
Kaplan-Meier Progression-Free Survival Plots of Patients with Different Types of EOC Stratified by FYN Expression and FIGO Stage. A, clear cell carcinomas (CCC); B, high-grade serous carcinomas (HGSC); C, other high-grade carcinomas; D, low-grade carcinomas
See this image and copyright information in PMC

References

    1. Donehower LA, Soussi T, Korkut A, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28:1370–84 e5. - PMC - PubMed
    1. Elias D, Ditzel HJ. FYN is an important molecule in cancer pathogenesis and drug resistance. Pharmacol Res. 2015;100:250–4. - PubMed
    1. Friedlander ML, Russell K, Millis S, et al. Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. Int J Gynecol Cancer. 2016;26:648–54. - PMC - PubMed
    1. Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021;31:605–16. - PubMed
    1. Jensen AR, Saito YD, Liao CH, et al. FYN Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. Clin Cancer Res. 2011;17:3112–22. - PMC - PubMed